Of note, a patient with RAS wild-type FGFR2 fused pancreatic cancer attained a deep and durable response, and it is now established that such alterations are seen in <1% patients with pancreatic ductal adenocarcinoma, indicating the need to identify these patients with clinical grade genotyping. This evidence concerns the gene FGFR2 and pancreatic ductal adenocarcinoma.